Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung disease
Biotech
With $30M, Oorja Bio breathes new life into fibrosis candidate
The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining lung structure and stability.
Darren Incorvaia
May 20, 2026 10:31am
Cash-strapped Quince finds salvation in reverse merger
May 18, 2026 10:32am
NIH loses another leader as heart, lung and blood director exits
Jan 13, 2026 4:00am
AirNexis swoops in with $200M series A for COPD asset
Jan 9, 2026 11:01am
Daiichi-Merck ph. 3 ADC program on pause after patient deaths
Dec 18, 2025 11:22am
Thermo Fisher launches biopsy test to assess lung rejection risk
Oct 9, 2025 10:50am